FinBoss.io
CSEN
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
  • Tools
  • Guides
  • FinBot
FinBoss.io
Crypto prices
Liquidation War
Crypto tools
Altcoin Season Index
Big players (on-chain)
Bitcoin halving countdown
Bear market radar
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Largest US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Markets
Stock indices
Commodities
Forex rates
Bear market radar
Famous investors' portfolios
Tools
Dashboards
Investor dashboardTrader dashboardBeginner dashboard
Calculators
Compound interestDCA calculatorDrawdown recovery
Compare
BrokersCrypto exchanges
Přehled sekce Tools →
Guides
FinBot
CSEN
Home
Stocks
Globus MED Inc
GM

Globus MED Inc

GMEDNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 6 of 87 tracked investors

$80.90
▼ 1.14%
Famous investorshold 6buying 0selling 0
Price (USD)
$80.90
Market cap
$10.9B
P/E ratio
20.7
Tracked investors holding
6 of 87
Next earnings
5 Nov 2026

Globus MED Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
84out of 100
  • Valuation68
  • Growth84
  • Profitability80
  • Quality75
  • Debt100
  • Stability96
In its favour
  • ✓Out of 100 USD of revenue, 17 USD is left as net profit.
  • ✓It has more cash than debt.
  • ✓Revenue grew 42.2% a year over 3 years.
  • ✓The analysts' average target is 25% above the price.
What to watch
  • Nothing notable from the statements.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Reasonably priced

For 1 USD of annual earnings you pay 20.7 USD. Based on next year's estimates 15.0 USD.

P/E
20.7×
P/S
3.5×
EV/EBITDA
10.3×

Is the company growing?

Growing
22
23
24
25

Revenue over 3 years grew 42.2% a year. Last year 5.9%.

Does it make money?

Good

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 20266 Aug 20261.341.12+19.6%
Mar 20267 May 20261.120.92+21.7%
Dec 202524 Feb 20261.281.06+20.8%
Sep 20256 Nov 20251.180.79+49.4%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

Chart GMED

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

6
RD
Ray Dalio
Bridgewater Associates
0.11%$27,809,466▲ +6.5%
MG
Mario Gabelli
GAMCO Investors
0.09%$10,209,435unchanged
JG
Joel Greenblatt
Gotham Asset Management
0.05%$22,364,413▲ +89.8%
JS
Jim Simons
Renaissance Technologies
0.02%$15,558,491New position
Ns
Norský státní fond
Norges Bank
0.01%$89,048,300New position
Šn
Švýcarská národní banka
Swiss National Bank
0.01%$17,862,344▲ +1.8%

Frequently asked questions

How much is Globus MED Inc (GMED) stock?

Globus MED Inc shares trade at $80.90, -1.14% over the last trading day. The price is delayed.

What is the market cap of Globus MED Inc?

The market cap of Globus MED Inc is about $10.9B and its price-to-earnings ratio (P/E) is 20.7.

Which big investors hold Globus MED Inc?

According to the latest 13F filings, 6 of 87 tracked investors hold Globus MED Inc, for example Ray Dalio, Mario Gabelli, Joel Greenblatt.

When will Globus MED Inc report its next results?

The next earnings report of Globus MED Inc is expected on 5 Nov 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

  • Cost of sales 33
  • Research 5.0
  • Operations and selling 44.1
  • Taxes and other 0.0
  • Net profit 18.3

Out of 100 USD of revenue, 18.3 USD is left as net profit.

Is it financially healthy?

Yes
Cash
595M USD
Debt
112M USD
Free CF
554M USD

It has more cash than debt.

Does it pay a dividend?

No dividend

The company pays no dividend. It reinvests the money or holds it.

What do analysts expect?

Buy
Average target
100.92 USD
Vs price
+25%

13 analysts. Their opinion is not a recommendation by FinBoss.io.

Which big investors hold it?

6 of 87

Among the tracked investors, Ray Dalio, Mario Gabelli, Joel Greenblatt and others hold the stock according to 13F filings.

Ratios

P/E
20.7×
Forward P/E
15.0×
P/B
2.3×
P/S
3.5×
PEG
1.49
EV/EBITDA
10.3×
Gross margin
69.0%
Operating margin
24.8%
Net margin
17.0%
ROE
11.8%
ROA
8.7%
Debt / equity
0.0×
Current ratio
4.6×
Revenue growth
5.9%
Earnings growth
-26.2%
Beta
0.96
Dividend
0.00%
Payout ratio
0%